Stifel raised the firm’s price target on Neurocrine (NBIX) to $183 from $174 and keeps a Buy rating on the share following a Q3 report the firm says was “highlighted by a clear Ingrezza beat, as well as another substantial beat on Crenessity.” The firm, which notes it previously raised its peak sales estimate for Crenessity in Q2, is again raising near-term estimates following “another exemplary quarter,” the analyst added.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $160 from $156 at RBC Capital
- Neurocrine price target raised to $146 from $145 at Mizuho
- Neurocrine price target raised to $147 from $124 at BMO Capital
- Neurocrine price target raised to $179 from $175 at Piper Sandler
- Neurocrine price target raised to $164 from $160 at Canaccord